Part I: Clinical Protocol and Data Management. The UCDCCC Office of Clinical Research (OCR), formerly the Clinical Trials Support Unit, is led by Associate Director for Clinical Research (Karen Kelly, MD) and OCR Executive Director (Cinda Lyon, RN). The OCR includes five units: operations, business, regulatory, phase I and clinical, thus providing cancer center investigators with a centralized resource providing a full repertoire of services to conduct clinical trials. The OCR staff work cohesively with the Investigators to provide subjects with exceptional care such that toxicities are minimized, trial adherence is maintained and data quality is achieved. Part II: Data and Safety Monitoring. All clinical trials conducted under the auspices of UCDCCC include provisions for data and safety monitoring. The Data Safety and Monitoring Plan (DSMP) focuses on patient safety, protocol adherence and quality of data. It was recently revised to provide oversight of clinical trial conduct in accordance with NCI guidelines. Part III: Inclusion of Minorities and Women in Clinical Trials. The UCDCCC is dedicated to the inclusion of women and minorities in our cancer clinical trials and complies with the NIH regulations on accrual of these populations. Entry criteria for cancer studies are disease, not gender or ethnicity specific. The sex/gender and racial/ethnic makeup of the study population for any one trial will be influenced by the frequency of the diagnosis in various subgroups. We offer clinical trials focused on cancers for which minority populations experience disparities, for example, liver cancer (Asian Americans and all populations of color), prostate cancer (African Americans and Hispanics), and breast cancer (African Americans, Hispanics, and Asian Americans). Although protocols are open to women who meet the eligibility criteria, pregnant and nursing women are excluded because of unknown risks of anti-neoplastic agents to fetuses and infants. Part IV: Inclusion of Children in Clinical Trials. UCDCCC, through the Pediatric Oncology Division, offers a large variety of clinical cancer research trials to the children of Sacramento and the surrounding area. These trials address a wide variety of pediatric malignancies, including (but not limited to) leukemia/lymphoma, osteosarcoma, Wilms Tumor and neuroblastoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA093373-14
Application #
9148406
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
14
Fiscal Year
2016
Total Cost
$282,197
Indirect Cost
$102,454
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91

Showing the most recent 10 out of 836 publications